FDA warns of drug interactions between Victrelis and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors

On Feb. 7, the U.S. Food and Drug Administration announced that drug interactions between the hepatitis C virus protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medications when they are used in combination. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here